Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,217

The DOI matches its Crossref record; 535 of the 535 references it cites were found in a registry or an index.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

Open access
Yatham, Lakshmi N, Kennedy, Sidney H, Parikh, Sagar V, Schaffer, Ayal, Beaulieu, Serge, Alda, Martin, O’Donovan, Claire, MacQueen, Glenda, McIntyre, Roger S, Sharma, Verinder, Ravindran, Arun, Young, L Trevor, Milev, Roumen, Bond, David J, Frey, Benicio N, Goldstein, Benjamin I, Lafer, Beny, Birmaher, Boris, Ha, Kyooseob, Nolen, Willem A, Berk, Michael · 2013 · Bipolar Disorders

Abstract

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2012: 00: 000–000. © 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd. The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first‐line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first‐line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first‐line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second‐line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not‐recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long‐acting injection, and adjunctive ziprasidone continue to be first‐line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third‐line options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bdi.12025

Cites

535 of 535 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. 10.4088/JCP.10m06618 · doi:10.4088/jcp.10m06618
  2. American Psychiatric Association, 2011, DSM‐5 Development: Bipolar and Related Disorders
  3. Feifel D, 2011, A naturalistic, single‐blind comparison of rapid dose administration of divalproex ER versus quetiapine in patients with acute bipolar mania, Innov Clin Neurosci, 8, 29
  4. 10.1002/hup.870 · doi:10.1002/hup.870
  5. 10.1111/j.1742-1241.2009.02116.x · doi:10.1111/j.1742-1241.2009.02116.x
  6. 10.4088/JCP.v61n1208 · doi:10.4088/jcp.v61n1208
  7. 10.1177/0091270009347870 · doi:10.1177/0091270009347870
  8. 10.1016/S0924-9338(10)71430-9 · doi:10.1016/s0924-9338(10)71430-9
  9. 10.1097/YIC.0b013e328329b199 · doi:10.1097/yic.0b013e328329b199
  10. Knesevich M, 2009, The Efficacy and Tolerability of Cariprazine in Acute Mania Associated With Bipolar I Disorder: A Phase II Trial [Abstract NR1‐049]
  11. Pfizer Inc, 2010, 3‐Week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
  12. Kemp DE, 2010, Predictive value of early improvement in bipolar depression trials: a post‐hoc pooled analysis of two 8‐week aripiprazole studies, Psychopharmacol Bull, 43, 5
  13. Ketter T, 2011, Presented at 164th Ann Mtg American Psychiatric Association
  14. Loebel A, 2012, Lurasidone Adjunctive to Lithium or Valproate for the Treatment of Bipolar I Depression: Results of a 6‐Week, Double‐Blind, Placebo‐Controlled
  15. Pfizer Inc, 2009, A Six‐Week Study Evaluating the Efficacy and Safety of GEODON in Patients With a Diagnosis of Bipolar I Depression
  16. Pfizer Inc, 2009, A Six‐Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression
  17. 10.3109/15622970903544638 · doi:10.3109/15622970903544638
  18. Li X, 2009, Drug Utilization of Pregnancy Category D or X Drugs Among Child‐Bearing Age Women With Depression or Bipolar Disorder in Medicaid [Abstract]
  19. Food and Drug Administration, 2011, Antipsychotic Drugs: Class Labeling Change—Treatment During Pregnancy and Potential Risk to Newborns
  20. Imaz ML, 2011, Obstetrical and neonatal outcomes following prenatal exposure to lithium, Bipolar Disord, 13, 56
  21. Chessick C, 2011, Sensitivity and specificity of the Mood Disorder Questionnaire in the perinatal population, Bipolar Disord, 13, 35
  22. American Psychiatric Association, 2012, DSM‐5 Proposed Revision: Disruptive Mood Dysregulation Disorder
  23. 10.1176/appi.ps.60.8.1098 · doi:10.1176/appi.ps.60.8.1098
  24. Evans‐Lacko SE, 2010, Evaluation of guideline‐concordant care for bipolar disorder among privately insured youth, Prim Care Companion J Clin Psychiatry, 12, e1
  25. 10.1001/jama.2009.1152 · doi:10.1001/jama.2009.1152
  26. Young AH, 2010, The efficacy of quetiapine monotherapy in bipolar II depression: combined data from the BOLDER and EMBOLDEN studies, Bipolar Disord, 12, 58
  27. Kemp DE, 2011, Long‐term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine, Bipolar Disord, 13, 60
  28. Burdick K, 2011, Cognitive enhancement in euthymic bipolar patients with pramipexole: a placebo‐controlled adjunctive trial, Bipolar Disord, 13, 33
  29. Food and Drug Administration, 2011, FDA Drug Safety Communication: Serious Allergic Reactions Reported With the Use of Saphris (Asenapine Maleate)
  30. Cazorla P, 2011, Incidence, onset, and duration of treatment emergent somnolence with asenapine in patients with schizophrenia or bipolar disorder, Bipolar Disord, 13, 34
  31. 10.2190/PM.39.4.h · doi:10.2190/pm.39.4.h

Cited by

See all 1,217

Metadata

Authors
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., Young, L. T., Milev, R., Bond, D. J., Frey, B. N., Goldstein, B. I., Lafer, B., Birmaher, B., Ha, K., Nolen, W. A., & Berk, M.
Venue
Bipolar Disorders
Publisher
Wiley
Published
2012-12-12
Volume
15
Issue
1
Pages
1-44
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W1969114959
Cited by
1,217
References
535
FWCI
85.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.